{"id":"W2518387705","doi":"10.1182/blood.v126.23.496.496","title":"Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Open label; Off-label use; Internal medicine; Phases of clinical research; Phase (matter); Oncology; Randomized controlled trial; Clinical trial; Leukemia; Chronic lymphocytic leukemia; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007432487,0.002141736,0.002376103,0.0006055955,0.0007630701,0.001586985,0.001437637,0.002106166,0.00522124],"category_scores_gemma":[0.003601062,0.0008989276,0.002033933,0.0004135475,0.001750089,0.001353684,0.0008051451,0.003900816,0.001132878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001335428,"about_ca_system_score_gemma":0.00403198,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00102163,"about_ca_topic_score_gemma":0.002610856,"domain_scores_codex":[0.9968059,0.002275469,0.000123294,0.0002505506,0.0001590614,0.0003856526],"domain_scores_gemma":[0.9972555,0.0005312797,0.000547095,0.000248202,0.0002242464,0.001193715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9233734,0.03776137,0.002784162,0.0003672142,0.001005243,0.00008804245,0.0001385082,0.0006677504,0.008936924,0.0002265668,0.002163731,0.02248709],"study_design_scores_gemma":[0.8123282,0.1815061,0.002857087,0.00002562171,0.0003443371,0.00005460811,0.00002668615,0.0002376454,0.001175197,0.0001526569,0.001270515,0.00002139125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9748994,0.002011638,0.001470789,0.00118408,0.0002745177,0.01415004,0.003271435,0.0001728704,0.002565206],"genre_scores_gemma":[0.969814,0.001054844,0.004672637,0.001471004,0.0003334378,0.01434034,0.004956004,0.00005672421,0.003301009],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007432487,"threshold_uncertainty_score":0.03930724,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03257745358785442,"score_gpt":0.34248132132296,"score_spread":0.3099038677351056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}